Prohibition Era1970

The Controlled Substances Act of 1970: Nixon & Schedule I Classification

How Nixon's Controlled Substances Act placed cannabis in Schedule I alongside heroin — ignoring his own commission's recommendations and shaping drug policy for 50+ years.

1970

Time Period

Historical era

Key Figures

Historical actors

Sections

In-depth coverage

FAQs

Common questions

Overview

The Controlled Substances Act (CSA) of 1970 replaced the patchwork of existing federal drug laws with a unified framework that classified drugs into five schedules based on their medical utility and abuse potential. Cannabis was placed in Schedule I — the most restrictive category, reserved for substances with 'no currently accepted medical use' and 'a high potential for abuse' — alongside heroin and LSD. The placement was intended to be temporary. Congress created the Shafer Commission to study marijuana and recommend its permanent scheduling. When the commission concluded in 1972 that marijuana should be decriminalized, President Nixon rejected the findings outright. Cannabis has remained in Schedule I for over fifty years, creating enormous obstacles for medical research, blocking federal legalization, and providing the legal foundation for millions of arrests. The CSA's impact extends far beyond scheduling. It established the legal framework for the Drug Enforcement Administration (created in 1973), authorized asset forfeiture, enabled military-style drug enforcement, and created federal mandatory minimum sentences. The Act remains the single most consequential piece of drug legislation in American history.

The Controlled Substances Act emerged from the political turmoil of the late 1960s. The Marihuana Tax Act had been struck down by the Supreme Court in Leary v. United States (1969), leaving federal marijuana law in limbo. Nixon, who had campaigned on 'law and order,' seized the opportunity to construct a comprehensive federal drug enforcement framework that would serve both public health and political purposes.

The CSA's scheduling system classifies drugs into five categories. Schedule I substances are deemed to have no accepted medical use, high abuse potential, and no accepted safety for use under medical supervision. Schedule II through V represent decreasing levels of restriction. Cannabis was placed in Schedule I alongside heroin and LSD, while cocaine and methamphetamine were classified as Schedule II — technically considered less dangerous and more medically useful than marijuana.

Nixon appointed Pennsylvania Governor Raymond Shafer to lead the National Commission on Marijuana and Drug Abuse in 1971, expecting the commission to validate his hardline approach. Instead, the Shafer Commission's 1972 report, 'Marihuana: A Signal of Misunderstanding,' recommended decriminalizing personal use and concluded that marijuana did not cause the harms attributed to it. Nixon publicly rejected the report and refused to even read it.

John Ehrlichman, Nixon's domestic policy advisor, provided perhaps the most revealing explanation of the administration's drug policy in a 1994 interview published in Harper's Magazine in 2016. Ehrlichman stated: 'The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and Black people... We knew we couldn't make it illegal to be either against the war or Black, but by getting the public to associate the hippies with marijuana and Blacks with heroin, and then criminalizing both heavily, we could disrupt those communities.'

The DEA was established in 1973 to enforce the CSA, consolidating multiple federal drug enforcement agencies into a single entity. With a budget that would grow to over $3 billion annually, the DEA became the primary instrument of federal drug policy. Its role in maintaining cannabis as Schedule I has been pivotal — the agency has rejected every petition to reschedule marijuana, most recently in 2016, citing the same 'no accepted medical use' standard despite growing evidence to the contrary.

Schedule I classification has created a catch-22 for cannabis research. Scientists seeking to study marijuana must obtain DEA approval, use cannabis from a single federally authorized source (the University of Mississippi), and navigate a bureaucratic approval process that can take years. This has severely limited the clinical research needed to demonstrate the 'accepted medical use' required to reschedule — effectively using the lack of research caused by scheduling as justification for continued scheduling.

Key Figures

Richard Nixon

President who signed the CSA and rejected the Shafer Commission

Raymond Shafer

commission chair who recommended decriminalization

John Ehrlichman

Nixon advisor who admitted the War on Drugs targeted political enemies

John Mitchell

Attorney General who shaped the CSA's enforcement provisions

Historical Significance

The Controlled Substances Act placed cannabis in Schedule I — the most restrictive drug category — creating the legal foundation for over 50 years of prohibition, millions of arrests, and severe barriers to medical research.

Frequently Asked Questions

Why is cannabis classified as Schedule I?

Cannabis was placed in Schedule I in 1970 as a temporary measure while the Shafer Commission studied it. When the commission recommended decriminalization, Nixon rejected the findings. Cannabis has remained Schedule I for over 50 years, classified alongside heroin as having 'no accepted medical use' despite evidence to the contrary.

What does Schedule I mean?

Schedule I is the most restrictive drug classification under the Controlled Substances Act. It designates substances as having no accepted medical use, high abuse potential, and no accepted safety for use under medical supervision. This classification creates severe barriers to research and blocks most legal uses.

How does Schedule I affect cannabis research?

Schedule I creates a research catch-22. Scientists need DEA approval, must use cannabis from a single federal source, and face years-long approval processes. The resulting lack of research is then cited as evidence that cannabis has 'no accepted medical use' — the very standard needed to reschedule.

Is cannabis being rescheduled?

In 2023, the HHS recommended rescheduling cannabis to Schedule III. The DEA initiated a review process. Rescheduling to Schedule III would acknowledge medical use, ease research barriers, and provide significant tax relief to cannabis businesses under IRC Section 280E, though it would not legalize recreational use.